Advertisement
Home Tags Multiple Myeloma

Tag: Multiple Myeloma

World Trade Center-exposed firefighters have increased prevalence of monoclonal gammopathy of undetermined significance (MGUS) and light-chain MGUS

Multiple Myeloma Risk May Be Up for WTC-Exposed Firefighters

And, cancer burden projected to be greater than expected for world trade center-exposed firefighters
Amplification of the inflammation-responsive RNA editase adenosine deaminase acting on RNA (ADAR)1 gene is associated with reduced survival in multiple myeloma

Multiple Myeloma Survival Down With High ADAR1 RNA Expression

ADAR1 knockdown reduces regeneration of high-risk multiple myeloma in patient-derived xenografts
For heavily pre-treated patients with relapsed/refractory multiple myeloma

VDT PACE Effective in Relapsed, Refractory Multiple Myeloma

Minimal response or more in 68.4 percent of patients, partial response or more in 54.4 percent
Women with a longer history of breastfeeding may be less likely to develop multiple sclerosis than mothers who never breastfed or nurse for briefer periods

Breastfeeding Appears to Lower the Risk of Multiple Sclerosis

Benefits reported for women who nursed 15 months or more
A new type of immunotherapy appears to provide long-lasting protection against multiple myeloma

ASCO: CAR T-Cell Therapy Promising in Multiple Myeloma

Findings from trial of chimeric antigen receptor T cells targeting B-cell maturation protein
There is a substantial financial burden for Medicare beneficiaries with myeloma who do not receive a low-income subsidy for orally-administered anticancer therapy

High Costs for Myeloma Patients Not Getting Low-Income Subsidy

For those aged 75 to 84 years, LIS receipt linked to increased odds of receiving immunomodulatory drugs
Combination therapy with lenalidomide

Combo Rx Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

Longer progression-free survival, but no significant difference in overall survival at four years
Use of zoledronic acid every 12 weeks does not result in increased risk of skeletal events compared with use every four weeks among patients with bone metastases due to breast cancer

Zoledronic Acid Every 12 Weeks Noninferior in Bone Metastases

No increase in risk of skeletal events versus treatment every four weeks for bone metastases
In patients with multiple myeloma

Thalidomide May Cause Epidermal Necrolysis in Multiple Myeloma

Case report describes toxic epidermal necrolysis in patient with multiple myeloma receiving thalidomide
Adding daratumumab to standard treatment for advanced cases of multiple myeloma may significantly improve patients' chances of a response and even recovery

Adding Daratumumab to Standard Tx Effective in Multiple Myeloma

43.1 percent of study patients had a complete response